Tag Archives: Soligenix

Soligenix’s ThermoVax able to stabilize vaccines up to one year

Soligenix, a Princeton, New Jersey-based clinical stage biopharmaceutical company, announced positive results on Wednesday for a study involving its vaccine heat stabilization technology, ThermoVax. Continue Reading

Continue Reading

Soligenix Appoints Richard Straube, MD, as Chief Medical Officer

Princeton, NJ – January 6, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as […]

Continue Reading

Soligenix Announces Initiation of a Phase 2 Clinical Trial of orBec® for the Treatment of Chronic GI GVHD

Clinical Trial Supported by $300,000 NCI Grant  Princeton, NJ – December 2, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that […]

Continue Reading

FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome

Princeton, NJ – September 16, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) […]

Continue Reading

Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn’s Disease

Princeton, NJ – May 15, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate […]

Continue Reading

Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis

Princeton, NJ – March 27, 2013 -Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in […]

Continue Reading

Soligenix Announces Significant Progress with ThermoVax™ Towards the Development of Heat Stable Vaccines

Research Conducted under $9.4 Million NIAID Cooperative Grant Princeton, NJ – March 19, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today key progress in the development of ThermoVax™, its proprietary vaccine thermostabilization technology. Several complementary preclinical studies have indicated the potential for high temperature stability for […]

Continue Reading

Soligenix Submits BARDA Contract Proposal for Development of OrbeShield™ in GI ARS

Princeton, NJ – February 20, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today submission of a full contract proposal to the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures. This submission supports a potential multi-year, multi-million dollar […]

Continue Reading

Soligenix to Present at 15th Annual BIO CEO & Investor Conference

Presentation to be Webcast Live, 3 PM EST, February 12th Princeton, NJ – February 12, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2013 BIO CEO & Investor […]

Continue Reading

FDA Grants Soligenix Fast Track Designation for OrbeShieldTM for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)

Princeton, NJ – January 29, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its OrbeShield™ (oral beclomethasone 17,21-dipropionate or oral BDP) development program for the treatment of GI ARS has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA). Soligenix has also […]

Continue Reading
Follow

Get every new post delivered to your Inbox.

Join 86 other followers